KR101525548B1 - 내피세포 특이성을 나타내는 프로모터 및 혈관신생의 조절을 위한 그 프로모터의 사용 방법 - Google Patents

내피세포 특이성을 나타내는 프로모터 및 혈관신생의 조절을 위한 그 프로모터의 사용 방법 Download PDF

Info

Publication number
KR101525548B1
KR101525548B1 KR1020097024041A KR20097024041A KR101525548B1 KR 101525548 B1 KR101525548 B1 KR 101525548B1 KR 1020097024041 A KR1020097024041 A KR 1020097024041A KR 20097024041 A KR20097024041 A KR 20097024041A KR 101525548 B1 KR101525548 B1 KR 101525548B1
Authority
KR
South Korea
Prior art keywords
delete delete
cells
promoter
angiogenesis
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097024041A
Other languages
English (en)
Korean (ko)
Other versions
KR20100017114A (ko
Inventor
드로 하라츠
쇼샤나 그린버거
에얄 브라이트바르트
리브나트 밴지오
미가엘 펠레드
Original Assignee
바스큘라 바이오제닉스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바스큘라 바이오제닉스 리미티드 filed Critical 바스큘라 바이오제닉스 리미티드
Publication of KR20100017114A publication Critical patent/KR20100017114A/ko
Application granted granted Critical
Publication of KR101525548B1 publication Critical patent/KR101525548B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
KR1020097024041A 2007-04-30 2008-04-27 내피세포 특이성을 나타내는 프로모터 및 혈관신생의 조절을 위한 그 프로모터의 사용 방법 Expired - Fee Related KR101525548B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/790,992 2007-04-30
US11/790,992 US20070286845A1 (en) 2000-11-17 2007-04-30 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
PCT/IL2008/000543 WO2008132729A2 (en) 2007-04-30 2008-04-27 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Publications (2)

Publication Number Publication Date
KR20100017114A KR20100017114A (ko) 2010-02-16
KR101525548B1 true KR101525548B1 (ko) 2015-06-15

Family

ID=38895566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097024041A Expired - Fee Related KR101525548B1 (ko) 2007-04-30 2008-04-27 내피세포 특이성을 나타내는 프로모터 및 혈관신생의 조절을 위한 그 프로모터의 사용 방법

Country Status (11)

Country Link
US (2) US20070286845A1 (https=)
EP (1) EP2152317A4 (https=)
JP (1) JP2010525805A (https=)
KR (1) KR101525548B1 (https=)
CN (2) CN103276015A (https=)
AU (1) AU2008243817B2 (https=)
CA (1) CA2685394A1 (https=)
MX (1) MX2009011750A (https=)
NZ (1) NZ581511A (https=)
WO (1) WO2008132729A2 (https=)
ZA (1) ZA200908331B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
CN100506284C (zh) * 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
EP2310507A4 (en) * 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
AU2011204407B2 (en) * 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
NZ601324A (en) * 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
JP6009357B2 (ja) * 2010-01-12 2016-10-19 バスキュラー バイオジェニックス リミテッド アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
KR20140027063A (ko) * 2010-10-28 2014-03-06 버지니아 커먼웰스 유니버시티 치료와 병용하는 암 영상화: 치료진단
ES2680636T3 (es) 2011-02-14 2018-09-10 Revivicor Inc. Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos
PL2908865T3 (pl) 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
CN107630004B (zh) 2017-09-01 2021-01-15 康希诺生物股份公司 降低可复制性腺病毒产生的细胞株及构建方法和应用
JP2021500355A (ja) 2017-10-20 2021-01-07 バスキュラー バイオジェニックス リミテッド 抗血管新生薬剤療法のための診断方法
KR20210139329A (ko) 2019-03-13 2021-11-22 바스큘라 바이오제닉스 리미티드 항종양 요법의 방법
MX2021012398A (es) 2019-04-12 2021-11-12 Vascular Biogenics Ltd Metodos de terapia antitumoral.
CN110714028B (zh) * 2019-11-04 2021-08-31 中国人民解放军第四军医大学 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体
CN114457003A (zh) 2020-11-10 2022-05-10 维思尔治疗有限公司 预调节血管细胞用于转导的方法、转导方法和保存转导的细胞的方法
CA3232376A1 (en) * 2021-09-20 2023-03-23 Maria KOKKINAKI Multitransgenic pigs comprising ten genetic modifications for xenotransplantation
FR3158516A1 (fr) * 2024-01-23 2025-07-25 Asfalia Biologics Production de vecteurs toxiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106559A1 (en) * 2002-02-01 2005-05-19 Philippa Radcliffe Viral vector
US20050176632A1 (en) * 2002-02-04 2005-08-11 Tetsuya Ohtaki Angiogenesis inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US207985A (en) * 1878-09-10 Improvement in grain-separators
US4866042A (en) * 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5906827A (en) * 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US5747340A (en) * 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
AU719629B2 (en) * 1996-11-08 2000-05-11 Oklahoma Medical Research Foundation Endothelium specific expression regulated by EPCR control elements
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6206917B1 (en) * 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
ES2320603T3 (es) * 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
EP0909532A1 (en) * 1997-10-16 1999-04-21 Development Center For Biotechnology Environmentally compatible porous material comprising beneficial nematodes and its preparation
JP2001521786A (ja) * 1997-10-30 2001-11-13 ザ ジュネラル ホスピタル コーポレーション 単離軟骨細胞を使用した軟骨性基質の接着
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
CA2331844A1 (en) * 1998-05-07 1999-11-11 University Of Maryland, Baltimore A method for diagnosing and treating chronic pelvic pain syndrome
US6239151B1 (en) * 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6576265B1 (en) * 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) * 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6265216B1 (en) * 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
US6652583B2 (en) * 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
ES2425321T3 (es) * 2000-11-17 2013-10-14 Vascular Biogenics Ltd. Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos
US7067649B2 (en) * 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
US6438802B1 (en) * 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
CN100506284C (zh) * 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
CN1424401A (zh) * 2003-01-06 2003-06-18 李川源 有条件复制型腺病毒及其构建方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106559A1 (en) * 2002-02-01 2005-05-19 Philippa Radcliffe Viral vector
US20050176632A1 (en) * 2002-02-04 2005-08-11 Tetsuya Ohtaki Angiogenesis inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Journal of Biological Chemistry, Vol. 272, No. 51, pp. 32613-32622 (1997.12.19.) *

Also Published As

Publication number Publication date
CN101808669A (zh) 2010-08-18
NZ581511A (en) 2012-02-24
MX2009011750A (es) 2010-04-27
CA2685394A1 (en) 2008-11-06
ZA200908331B (en) 2010-12-29
EP2152317A2 (en) 2010-02-17
CN103276015A (zh) 2013-09-04
JP2010525805A (ja) 2010-07-29
US20070286845A1 (en) 2007-12-13
WO2008132729A2 (en) 2008-11-06
EP2152317A4 (en) 2012-11-14
KR20100017114A (ko) 2010-02-16
WO2008132729A3 (en) 2009-10-22
AU2008243817B2 (en) 2013-09-19
US20140155467A1 (en) 2014-06-05
AU2008243817A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
KR101525548B1 (ko) 내피세포 특이성을 나타내는 프로모터 및 혈관신생의 조절을 위한 그 프로모터의 사용 방법
EP2174668B1 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
AU2011205076B2 (en) Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
HK1143078B (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
IL201760A (en) Nucleic acid vectors for inhibiting angiogenesis
IL209034A (en) Promoters with endothelial cell specificity and methods for their use in angiogenesis control
IL183187A (en) Nucleic acid constructs and preparations for inhibiting angiogenesis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180518

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190516

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230529

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230529